Abstract:
The present invention relates to the field of recombinant production of biological molecules in genetically modified cells. More particularly, it relates to a method for recombinant production of human milk oligosaccharides (HMO) using a genetically modified cell expressing a protein of the major facilitator superfamily (MFS), the protein expressed being Bad.
Abstract:
The present inventive concept relates to a genetically modified cell enabled for the production of an oligosaccharide, preferably, an HMO, comprising a recombinant nucleic encoding a putative transporter protein of the MFS superfamily; and methods using said cell for the production of oligosaccharide(s), preferably an HMO.
Abstract:
The present inventive concept relates to a genetically modified cell enabled for the production of an oligosaccharide, preferably, an HMO, comprising a recombinant nucleic acid encoding a protein of the MFS superfamily; and methods using said cell for the production the oligosaccharide, preferably an HMO.
Abstract:
The invention relates to a human milk oligosaccharide (HMO) for use in, a synthetic composition comprising an HMO for use in and a method for preventing or treating migraine in a human.
Abstract:
The invention relates to a microbial production of recombinant oligosaccharides, particularly of human milk oligosaccharides (HMOs), using a genetically modified microorganism, particularly E. coli , in antibiotic-free cultivating medium.
Abstract:
The application relates to synthetic compositions containing one or more human milk mono- or oligosaccharides for use treating irritable bowel syndrome and symptoms relating to irritable bowel syndrome. The HMS is preferably selected from sialic acid and fucose and the HMO is preferably selected from 2'-fucosyllactose (2'-FL), 3-fucosyllactose (3-FL), difucosyllactose (DFL), 3'-sialyllactose (3'-SL), 6'-sialyllactose (6'-SL), lacto-N-tetraose (LNT), lacto-N-neotetraose (LNnT), lacto-N-fucopentaose (LNFP-I) and 3',6-disialyllacto-N- tetraose (DSLNT).
Abstract:
This invention relates to achemo-enzymatic synthesis of oligosaccharides of formula 1 I wherein R is selected from -OH, -N 3 and -OR 6 wherein R 6 is selected from allyl optionally substituted by one or more methyl, propargyl optionally substituted by one or more methyl, 2-trimethylsilyl-ethyl, -(CH 2 ) n -NH 2 and -(CH 2 ) n -N 3 wherein integer n is to 10,preferably 2 or 3, R is selected from sialyl moiety, -SO 3 H and -CH(R )-COOH wherein R is selected from H, alkyl and benzyl, R 2 is selected from H and fucosyl, R 3 is selected from H and sialyl, R 4 is selected from H and fucosyl, provided that at leastone of R 3 and R 4 is H, and A is a divalent carbohydrate linker, having important biological activities and significant commercial value for the pharmaceutical and food industry.
Abstract:
The invention relates to a method for making an N -substituted D-mannosamine derivative of the following formula 1 and its salts wherein R 1 is a non-electron-withdrawing group,and wherein R 2 is -OH or R 2 is –NHR 3 wherein R 3 is a group removable by hydrogenolysis; by epimerizingan N -substituted D-glucosamine derivative of the following formula 2 wherein R 1 and R 2 are as defined above.
Abstract:
A method for modifying galactosyl disaccharides in order to enhance their bifidogenic effect, comprising reacting at least one glycosyl donor with a precursor galactosyl disaccharide or a mixture of precursor galactosyl disaccharides using enzyme catalysis, compounds obtainable by said method and the use of such compounds in consumable products.